Collegium Pharmaceutical (NASDAQ:COLL) Stock Price Crosses Below Fifty Day Moving Average - Should You Sell?

Key Points

• Shares of Collegium Pharmaceutical fell below its 50-day moving average (50‑day MA $39.56), trading as low as $33.06 and last at $35.25 on a volume of 568,868, a bearish technical signal.
• Analysts are mixed but the consensus is a Moderate Buy with a $53.40 average target (four Buys, three Holds), and several firms have recent price targets in the high‑$50s.
• Collegium missed Q results (EPS $2.04 vs. $2.20 estimate) despite revenue rising 12.9% YoY, and insiders recently sold material stakes (EVPs sold ~63,952 shares combined), leaving insiders with 2.51% ownership.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) shares passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $39.56 and traded as low as $33.06. Collegium Pharmaceutical shares last traded at $35.25, with a volume of 568,868 shares traded.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Zacks Research cut shares of Collegium Pharmaceutical from a "strong-buy" rating to a "hold" rating in a report on Tuesday, January 6th. Needham & Company LLC reiterated a "buy" rating and set a $56.00 target price (up from $54.00) on shares of Collegium Pharmaceutical in a report on Thursday, March 19th. Truist Financial set a $58.00 price target on shares of Collegium Pharmaceutical in a research report on Tuesday, February 10th. HC Wainwright restated a "buy" rating and issued a $60.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, March 20th. Finally, Weiss Ratings lowered Collegium Pharmaceutical from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Thursday, March 5th. Four research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, Collegium Pharmaceutical currently has a consensus rating of "Moderate Buy" and a consensus target price of $53.40.

Collegium Pharmaceutical Stock Performance

The stock has a 50-day moving average price of $39.56 and a 200 day moving average price of $41.46. The company has a quick ratio of 1.48, a current ratio of 1.57 and a debt-to-equity ratio of 2.59. The firm has a market capitalization of $1.14 billion, a price-to-earnings ratio of 20.61 and a beta of 0.77.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, missing the consensus estimate of $2.20 by ($0.16). Collegium Pharmaceutical had a net margin of 8.05% and a return on equity of 98.65%. The firm had revenue of $205.45 million during the quarter, compared to analyst estimates of $206.36 million. During the same period last year, the business earned $1.77 EPS. The firm's revenue was up 12.9% compared to the same quarter last year. On average, analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Insiders Place Their Bets

In related news, EVP David Dieter sold 13,976 shares of the business's stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $34.92, for a total transaction of $488,041.92. Following the completion of the transaction, the executive vice president owned 77,071 shares in the company, valued at approximately $2,691,319.32. The trade was a 15.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Scott Dreyer sold 49,976 shares of the firm's stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total value of $2,019,530.16. Following the completion of the sale, the executive vice president owned 71,770 shares in the company, valued at approximately $2,900,225.70. This represents a 41.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 2.51% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several hedge funds and other institutional investors have recently made changes to their positions in COLL. Group One Trading LLC acquired a new position in Collegium Pharmaceutical in the fourth quarter valued at approximately $28,000. Caitong International Asset Management Co. Ltd raised its holdings in Collegium Pharmaceutical by 205.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company's stock worth $29,000 after purchasing an additional 427 shares in the last quarter. Federated Hermes Inc. raised its holdings in Collegium Pharmaceutical by 67.0% during the third quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company's stock worth $31,000 after purchasing an additional 350 shares in the last quarter. Hantz Financial Services Inc. lifted its position in shares of Collegium Pharmaceutical by 137.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company's stock worth $60,000 after buying an additional 993 shares during the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of Collegium Pharmaceutical during the 4th quarter worth approximately $61,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company's core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company's principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.